Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

12/21/2012 | 05:46am US/Eastern

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.


-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at

Subscribe to WSJ:

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
Recommend :
React to this article
Latest news on MERCK & CO., INC.
4d ago MERCK & CO : ex-dividend day
7d ago MERCK : to Participate at the Morgan Stanley Global Healthcare Conference
09/08 MERCK : The first company to join the future life science cluster in Stockholm U..
09/05 DOW MOVERS : Gs, wmt
09/05 MERCK : Upcoming Presentations, Technical Update, Study Results, and Marketing A..
09/04 MERCK : FDA okays new immune system cancer drug
09/04 MERCK : Studies from Merck & Company Update Current Data on Biotechnology (Micro..
09/04 MERCK : FDA OKs Merck drug, 1st in new cancer drug class
09/04 MERCK : Report Summarizes Cytokines Study Findings from Merck & Company (Interle..
09/04 MERCK : Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FD..
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
Merck _ Co., Inc. : Income Statement Evolution
More Financials
Dynamic quotes